Moreover, the increased CD8+ Ki67+ T cells and MHC-II expression of CD11c+ DCs after combination treatment suggested the proliferation of CD8+ T cells and activation of DCs in the tumor-draining lymph nodes (Figure S5A-D). Here, ITGAX is linked to neoplasm.